P2, N=140, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center

The tumor was mismatch repair proficient and did not express claudin-18.2 and human epidermal growth factor receptor 2. Programmed death-ligand 1 combined positive score was <10. Based on the results of genetic expression, chemotherapy comprised of tegafur-gimeracil-oteracil potassium, oxaliplatin and nivolumab was considered; however, the patient rapidly deteriorated and died of progression of underlying cancer 39 days following the initial visit to our hospital.

High-risk patients exhibited poorer survival, increased immune cell (particularly T cell) infiltration, higher sensitivity to chemotherapeutics like 5-fluorouracil and paclitaxel, and a higher TP53 mutation rate. Additionally, SSRP1 and SETDB1 were verified to promote the proliferation and invasion of HCC cells. This integrated model, combining genomic and immunological features, is a reliable prognostic tool for HCC patient stratification and personalized chemotherapy, promising for clinical translation and precision medicine in HCC.

Maintenance capecitabine significantly prolonged PFS compared to surveillance, meeting the primary endpoint and supporting its use to extend disease control in advanced OGA.

The serum containing HRCR was prepared, and a blank group, a 5-fluorouracil(5-FU) group, and serum containing HRCR groups(low, medium, and high doses) were established...Through combined treatment of the mitophagy inhibitor Mdivi-1 and HRCR, the inhibitory effect of HRCR on cell proliferation could be further enhanced to promote HRCR-induced apoptosis. In conclusion, the serum containing HRCR can induce apoptosis through the inhibition of HT-29 cell proliferation and mitophagy, which are achieved by damaging mitochondrial morphology, reducing mitochondrial membrane potential, increasing ROS level, decreasing ATP content, and inhibiting the Parkin, PINK1, and LC3 signaling pathways, thereby exerting anti-colon cancer effects.

Capecitabine and paclitaxel demonstrated comparable efficacy after CDK4/6i progression, with no significant differences in PFS or OS. Given their distinct toxicity profiles, treatment selection should be individualized according to patient characteristics and tolerability.

In this cN + cohort, approximately one in six patients eligible for AST had residual disease only in the axilla. Less-invasive axillary staging procedures were associated with a low estimated theoretical risk of missed AST eligibility. However, these findings should be interpreted in light of the modest sample size.

The results of Study LIBRETTO-431, an ex-US multiregional, open-label, randomized, active-controlled trial of selpercatinib versus platinum-based and pemetrexed chemotherapy with or without pembrolizumab in patients with treatment-naïve advanced rearranged during transfection fusion-positive non-small cell lung cancer, highlight the challenges of interpreting OS in trials with high crossover rates and variable postprogression therapies. Trial results demonstrated a large improvement in progression-free survival with an acceptable safety profile, but were accompanied by an immature OS analysis with a hazard ratio of 1.26, favoring the chemoimmunotherapy arm. Regardless of the position of OS in the end point hierarchy, it is critical that OS analyses include prespecified plans for data collection and analytical methods to account for the potential impact of postprogression therapies on the interpretation of study results.

P1, N=33, Recruiting, The Methodist Hospital Research Institute | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Jun 2025 --> Jun 2026

Synergy with 5-fluorouracil (5-Fu) was evaluated using checkerboard assays and analyzed by SynergyFinder...This study demonstrates that terfenadine exerts multifaceted antitumor effects in GC through modulation of the PI3K/AKT/mTOR pathway, exhibits synergistic activity with 5-Fu, and shows in vivo efficacy in a clinically relevant PDX model. These findings support the repurposing of terfenadine as a promising therapeutic agent for GC.

The results showed that the cytotoxic effect of all three NBDs on KYSE-150 outperformed 5-fluorouracil (5-FU), with NBD 3 producing the highest cytotoxicity (IC50: 21.57 µM), followed by NBD 2 (IC50: 34.17 µM) and NBD 1 (IC50: 37.75 µM)...This study provides insights into the potential anticancer activities and the mechanistic pathway of NBDs in ESCC. The online version contains supplementary material available at 10.1007/s10616-026-00934-8.

We present the case of a 74-year-old man with Stage IVB lung adenocarcinoma who developed changes in his psychiatric symptoms following three cycles of treatment with cisplatin, pemetrexed, and pembrolizumab. This is the first documented case of anti-titin antibody-positive encephalitis in a patient with non-small cell lung cancer (NSCLC). This case highlights the importance of considering immune-mediated neurological complications during Immune Checkpoint Inhibitor (ICI) treatment and the value of early antibody detection and prompt immunosuppressive therapy.